Easl 2019 studies are ridiculous, tons of money wasted on stupid useless studies, never seen such idiocy, it was many years i stopped reading conferences.replicor is starting a trial in US for patients on nucs too bad it is not in europe.anyway last study and mention of US trial http://replicor.com/wp-content/uploads/2018/06/Replicor-ISVHLD-GHS-2018-FINAL.pdf
they re also going to subcutaneous and giving up pegintf which is not the best immune therapy
all drugs i saw on easl are failures, unless they show no hbsag clearance they should not even be approved and approved drugs that might work had indipendent trials stopped by drug maker birinapant.....drug makers are making whatever possible to interfere or stop cures/small pharma companies/small studies, we should also push replicor and start to be very very angry, some scientists/liver specilists are starting to speak up, it is time to have a cure (i hope they are preparing to push for replicor trials)
Hey Steff welcome back! Where were you. I am very happy to see u back and was missing u and ur wonderful answers. Thank you for coming back.
I am wondering if now with drugs like TAF, if everyone should take this, that way there is reduced chances or further damage from HBVDNA integration into the host geonome. If the side effects are not bad such as kidney damage people can take this drugs for life. There was a study shared here years ago that after 120 months of using NUCS, Integrated HBV was undetectable in most patients. Is this a better strategy than chasing a cure?
We don't have any other option than to continue the nucs. I don't understand whom for these drug developers are making new drugs when entire hbv community will wipe out either due to complication or due to age.
Since there is very low rate of new cases of hbv due to increased immunisation rate these drug projects will be dumped as there won't be enough patients in future to give profits.